Diaz Thomas E, Ives Emma C, Lazare Diana I, Buckland Daniel M
University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, NC, USA.
The Johns Hopkins Hospital, Baltimore, MD, USA.
NPJ Microgravity. 2024 Jul 23;10(1):76. doi: 10.1038/s41526-024-00414-3.
Effective medications will be required to maintain human health for long-duration space operations. Previous studies have explored the stability and potency of several of the medications used on the International Space Station (ISS). This study is a comprehensive analysis of the expected terrestrial shelf-lives of the entire 2023 ISS formulary using 4 international registries. Of the 106 medications in the ISS formulary, shelf-life data was found in at least 1 of the registries for 91 (86%) medications. Of these 91 medications, 54 have an estimated terrestrial shelf-life of ≤36 months when stored in their original packaging. 14 will expire in less than 24 months. The results of this study provide operational insight to supplying a pharmacy for an exploration mission, optimize therapeutic outcomes, and prevent diseases associated with extended spaceflight operations. Ultimately, those responsible for the health of spaceflight crews will have to find ways to extend the expiration of medications to the complete mission duration or accept the elevated risk associated with administration of an expired medication.
为了长期的太空任务维持人类健康，需要有效的药物。此前的研究已经探索了国际空间站（ISS）上使用的几种药物的稳定性和效力。本研究使用4个国际登记处，对2023年国际空间站全部配方药物的预期地面保质期进行了全面分析。在国际空间站配方中的106种药物中，在至少1个登记处找到了91种（86%）药物的保质期数据。在这91种药物中，54种储存在原包装中时，预计地面保质期≤36个月。14种将在不到24个月内过期。本研究结果为为探索任务提供药房、优化治疗效果以及预防与长期太空飞行任务相关的疾病提供了操作见解。最终，负责航天机组人员健康的人员将不得不设法将药物的保质期延长至整个任务持续时间，或者接受使用过期药物带来的更高风险。
